Intrathecal Enzyme Delivery for Blood-Brain Barrier Bypass
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current enzyme replacement therapies for treating CNS diseases are hindered by the blood-brain barrier, leading to inadequate delivery of therapeutic agents to the central nervous system, particularly for lysosomal storage disorders, with existing methods being invasive and ineffective.
Innovation Solution
Intrathecal administration of therapeutic enzymes at high concentrations (e.g., >3 mg/ml) directly into the cerebrospinal fluid, using simple saline or buffer-based formulations, allowing extensive diffusion across brain regions without significant adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If intravenous administration of therapeutic enzymes is used, then systemic delivery is achieved, but adequate penetration into CNS tissues is insufficient due to the blood-brain barrier
Solution Approach 1:
The patent uses cerebrospinal fluid (CSF) as an intermediary medium to deliver therapeutic enzymes to the CNS. By injecting enzymes into the CSF space, the blood-brain barrier is circumvented and enzymes can be distributed throughout the CNS without requiring vascular penetration, thus solving the delivery problem while avoiding the harmful effect of the barrier blockage
Solution Approach 2:
The patent replaces the mechanical/vascular delivery system (intravenous injection relying on blood circulation) with a chemical/fluiddynamic system (intrathecal injection relying on CSF flow and diffusion). This substitution allows enzyme delivery to the CNS without overcoming the blood-brain barrier physically, addressing both the delivery quantity and barrier blockage issues
2Quantity of substance
If direct intra-cranial injection of therapeutic agents is used, then delivery to brain tissue is achieved, but risk of complications and poor diffusion occur
Solution Approach 1:
The patent introduces CSF as an intermediary delivery medium that fills the subarachnoid space and distributes enzymes throughout the CNS without requiring direct penetration of brain tissue. This approach achieves therapeutic delivery while avoiding the harmful effects of direct tissue injection such as damage and infection risk
Solution Approach 2:
Instead of directly injecting into brain tissue, the patent uses CSF as a copying medium that naturally circulates around the CNS. The therapeutic enzymes are delivered into this existing fluid system, which then distributes them throughout the CNS spaces, achieving delivery without the harmful direct tissue penetration
3Quantity of substance
If intrathecal injection of therapeutic agents is used, then delivery to CSF is achieved, but binding to ependymal lining prevents diffusion
Solution Approach 1:
The patent modifies the concentration parameter of the therapeutic enzyme solution to achieve optimal delivery. By controlling the enzyme concentration in the intrathecal injection, the system achieves adequate delivery to CSF while minimizing non-specific binding to the ependymal lining, thus overcoming the diffusion barrier without sacrificing delivery quantity
4Quantity of substance
If high concentration of therapeutic enzymes is administered intrathecally, then extensive diffusion across brain regions is achieved, but adverse effects may occur
Solution Approach 1:
The patent optimizes the concentration parameter of intrathecal enzyme administration to achieve the desired balance. By carefully controlling the enzyme concentration in the CSF, the system achieves extensive diffusion and therapeutic effect while minimizing adverse effects, thus resolving the contradiction between delivery quantity and harmful effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Achieves effective and less invasive delivery of enzymes to deep brain regions, reducing GAG storage and increasing enzymatic activity, thereby treating CNS symptoms of lysosomal storage disorders.
Implementation Method 1
Intrathecal administration of therapeutic enzymes at high concentrations (e.g., >3 mg/ml) directly into the cerebrospinal fluid, using simple saline or buffer-based formulations, allowing extensive diffusion across brain regions
Data Source
AI summary
The present invention provides an effective and less invasive approach for direct delivery of therapeutic agents to the central nervous system (CNS). In some embodiments, the present invention provides methods including a step of administering intrathecally to a subject suffering from or susceptible to a lysosomal storage disease associated with reduced level or activity of a lysosomal enzyme, a composition comprising a replacement enzyme for the lysosomal enzyme.